StreetInsider.com News Articles

Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director

Wed, 01 Jul 2026 07:00:00 -0400

Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncology
His appointment will strengthen Step Pharma’s board as it advances dencatistat across three clinical programmes for essential thrombocythaemia (ET), lymphoma and solid tumours.

Saint-Genis-Pouilly, France, 1 July 2026 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Neil J. Gallagher, MD, PhD, as Non-Executive Director effective immediately. He will support the Company as it continues to advance its first-in-class CTPS1

Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director

Wed, 01 Jul 2026 07:00:00 -0400

Neil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncology
His appointment will strengthen Step Pharma’s board as it advances dencatistat across three clinical programmes for essential thrombocythaemia (ET), lymphoma and solid tumours.

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Lynch Thomas J. Jr.

Thu, 25 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260625/26692342.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Lynch Thomas J. Jr.

Thu, 25 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260625/26692342.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Duty Stuart

Thu, 25 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260625/26692323.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Duty Stuart

Thu, 25 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260625/26692323.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Biller Scott

Thu, 25 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260625/26692281.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Biller Scott

Thu, 25 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260625/26692281.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Mendelsohn Michael

Thu, 25 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260625/26692244.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Mendelsohn Michael

Thu, 25 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260625/26692244.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Gallagher Neil

Thu, 25 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260625/26692254.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Gallagher Neil

Thu, 25 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260625/26692254.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: SMITH IAN F

Thu, 25 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260625/26692235.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: SMITH IAN F

Thu, 25 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260625/26692235.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: GILL SIMBA

Thu, 25 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260625/26692215.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: GILL SIMBA

Thu, 25 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260625/26692215.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Cole Douglas G.

Thu, 25 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260625/26692190.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: Cole Douglas G.

Thu, 25 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260625/26692190.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: PARSHALL B LYNNE

Thu, 25 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260625/26692201.html

Form 4 Foghorn Therapeutics For: Jun 24 Filed by: PARSHALL B LYNNE

Thu, 25 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260625/26692201.html

Form 8-K Foghorn Therapeutics For: Jun 24

Wed, 24 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260624/26685433.html

Form 8-K Foghorn Therapeutics For: Jun 24

Wed, 24 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260624/26685433.html

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

Mon, 22 Jun 2026 08:30:00 -0400

AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

Mon, 22 Jun 2026 08:30:00 -0400

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology

Mon, 22 Jun 2026 08:30:00 -0400